Defining the right digital strategy for oncology: What do you want to measure?

Supported by:

21 August 2024

3:00pm

Shares

0

Share via

• Facebook
• Like
• Twitter
• Pinterest
• LinkedIn
• Digg
• Del
• Tumblr
• VKontakte
• Print
• Email
• Reddit
• Buffer
• Love This
• Weibo
• Pocket
• Xing
• Odnoklassniki
• WhatsApp
• Meneame
• Blogger
• Amazon
• Yahoo Mail
• Gmail
• AOL
• Newsvine
• HackerNews
• Evernote
• MySpace
• Mail.ru
• Viadeo
• Line
• Flipboard
• Comments
• Yummly
• SMS
• Viber
• Telegram
• Subscribe
• Skype
• Facebook Messenger
• Kakao
• LiveJournal
• Yammer
• Edgar
• Fintel
• Mix
• Instapaper
• Copy Link

Oncology clinical trials present some of the most complex challenges across clinical research, impacting enrolment, efficiency, and access. Thankfully, our industry is afforded a unique opportunity to address these issues with the evolving regulatory landscape, the burgeoning field of digital health technologies (DHTs), and the increasing adoption of decentralised and digital trial methods.

The US Food and Drug Administration (FDA)’s recent guidance on Direct-to-Patient (DTP) approaches, electronic Patient-Reported Outcomes (ePROs), and DHTs paves the way for incorporating patient-centric digital tools into trials.

According to PwC, the use of DHTs in clinical trials has grown by 97 percent within the last five years, and Tufts recognises that the appetite for collecting digital endpoints has doubled every three years since 2015.

As DHTs begin to help researchers define the new normal, it’s important to have the right strategy to define how you collect the right data to improve efficiency and experience. 

Learn how top 10 pharmaceutical companies are using a combination of DHTs, ePROs, clinical trial platforms and more, to ease oncology research and drastically reduce timelines. 

Key learning points

• The right questions to ask your team to help define a digital strategy as part of your clinical development programme. 
• Why the expanded use of digital measures and biomarkers will continue to accelerate clinical development timelines.
• How global pharmaceutical companies are benefiting from Medable’s novel approaches and technology to accelerate decision-making in oncology.

Interested? Fill out the form to register your place!

OUR SPEAKER

Musaddiq Khan – Vice President, Customer Value – Digital Outcomes & TA Strategy at Medable

Musaddiq Khan (Muz) is Vice President, Customer Value – Digital Outcomes & TA Strategy. He has been involved in clinical research for over 17 years. Most recently, he was the Director of Clinical Program Operations in the exploratory medicine & pharmacology group at Eli Lilly, where he led the operational delivery of the First-in-Human study on Lilly’s COVID-19 Antibody programme. Throughout his career, Muz has held various clinical operations roles in pharma, including PAREXEL, Roche and AstraZeneca. Muz completed his Executive MBA from the University of Cambridge with a dissertation on ‘Developing a Digital Health Strategy for Early Clinical Development’.

FAQs

FAQs 

Is the webinar free? 

Yes – there is no charge to watch the webinar, either live or on-demand. 

When will the webinar take place? 

21 August 2024 at 4.00pm GMT. 

Can I watch it later? 

The webinar will become available to watch on-demand shortly after the live webinar takes place. 

What are the benefits of attending live? 

You’ll be able to ask the speaker your questions, which will be answered live in the Q&A towards the end of the session. 

How long will the webinar be? 

This webinar will last up to an hour. 

What do I need to watch this webinar? 

All you need is a computer with an internet connection. We recommend using headphones if possible if you’re in an office environment.